Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying ...

GSK’s Exdensur is approved by the US FDA as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and ...

A study published in Neurology looks at the association between high fat cheese and dementia risk. Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, said: ...

Learn about women in STEM and the vital role of Dr Lidia Serina in advancing biopharma therapies and empowering women.

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

Drug trials offer people with cancer hope and free medicine, but they also create incentives for doctors in private clinics ...